Ternolol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ternolol

Property Description
Active ingredient Atenolol
Form Solid oral tablet
Pharmacological class Beta-adrenergic receptor antagonist (Beta-blocker)
Common use Modulation of heart rate and blood pressure
Origin Synthetic

Ternolol is a pharmaceutical preparation whose primary therapeutic component is the active ingredient Atenolol, the molecule defined by the World Health Organization (WHO) as the International Nonproprietary Name (INN). It is classified as a beta-adrenergic receptor antagonist, commonly known as a beta-blocker. Atenolol is a synthetic, single-ingredient compound that is designated as a cardioselective agent because it selectively blocks the beta1 adrenergic receptors primarily located in the heart. This specificity is clinically recognized for providing a focused pharmacological action, setting it apart from non-selective beta-blockers, which affect receptors throughout the body.

The chemical basis for Ternolol is the substance Atenolol (C14H22N2O3), which is manufactured through chemical synthesis. Ternolol is formulated for oral administration as a solid oral tablet. Pharmacological studies confirm that Atenolol is a hydrophilic beta-blocker with low lipid solubility, which means it is minimally processed by the liver and primarily eliminated from the body via the kidneys. This differentiation in metabolic pathways is often a key factor considered in patient profiles.

The general medical purpose of Ternolol is to provide targeted control over the cardiovascular system. Its core physiological action is to directly slow the heart rate and decrease the force of the heart muscle contraction. This mechanism reduces the overall strain and energy demand of the heart. The therapeutic goal of this action is to alleviate excessive hemodynamic stress and promote stable, efficient blood circulation throughout the body. This confirms the medicine is commonly used to reduce the heart’s workload and help normalize blood flow in patients requiring consistent cardiac modulation.

What side effects are possible with Ternolol?

The official safety profile of Ternolol (Atenolol) is established by government regulatory bodies, classifying potential experiences into frequency tiers and System-Organ Classes (SOCs). Tiredness and fatigue are among the Very Common (ge 1/10) adverse reactions documented in prescribing information. Reactions classified as Common (ge 1/100 to < 1/10) include bradycardia (slow heart rate), cold extremities, gastrointestinal disturbances, and dizziness.

Official Adverse Reaction Groupings

Adverse effects are documented across several physiological systems. Cardiac Disorders may include bradycardia and the precipitation of heart block or worsening of heart failure, which are considered serious adverse reactions. Effects related to the Nervous System may involve dizziness or paresthesia, while Psychiatric Disorders include sleep disturbances, mood changes, and, rarely, confusion or hallucinations.

Safety Constraints and Special Populations

Official labeling contains specific constraints concerning use. Abrupt cessation of therapy, particularly in individuals with Ischaemic Heart Disease, carries a documented risk of exacerbating angina pectoris or leading to myocardial infarction; gradual withdrawal is required. Furthermore, renal impairment necessitates a dose adjustment, as the medicine is primarily eliminated through the kidneys. In patients with diabetes, the medicine may mask signs of acute hypoglycemia. These classifications and constraints define the drug’s established safety characteristics without offering clinical advice.

Overdose and Emergency Response

Overdose and when to seek help

Ternolol overdose presents with severe cardiovascular depression, primarily characterized by pronounced hypotension (low blood pressure) and severe bradycardia (excessively slow heart rate). Regulatory documents state that these effects may rapidly escalate to life-threatening outcomes, including cardiogenic shock and asystole (cardiac arrest).

Documented non-cardiac manifestations include central nervous system effects such as seizures, confusion, and potentially coma, alongside metabolic imbalances like hypoglycemia (low blood sugar), metabolic acidosis, and bronchospasm in susceptible individuals.


If an overdose is suspected, immediate medical attention must be sought. This is a mandatory instruction from regulatory authorities because the management requires continuous hospital monitoring and specialized symptomatic and supportive treatment. It is required to contact emergency services or a Poisons Information Centre immediately.

No single specific antidote is documented; management relies on intensive measures such as the use of intravenous Glucagon, Atropine, and, in cases of renal impairment, hemodialysis. The pediatric population requires specific consideration due to the common manifestation of hypoglycemia.

Therapeutic Uses of Ternolol

Ternolol (Atenolol) is commonly applied across therapeutic domains relevant to cardiovascular and symptomatic management. It is generally used to help with managing symptoms that create noticeable physiological strain in chronic conditions, particularly those involving systemic imbalance and heightened physiological activity. Its primary uses focus on stabilizing heart function and lowering blood pressure.

Primary Therapeutic Applications

The medication is relevant for managing symptoms associated with conditions characterized by periods of heightened symptoms, such as Hypertension (high blood pressure), Angina Pectoris (chest pain), and specific forms of cardiac arrhythmias. It is also considered relevant as a prophylactic treatment to reduce the frequency and intensity of recurring migraine headaches. Ternolol plays a role in managing symptoms related to cardiovascular risk and assists with maintaining functional stability.

“Ternolol is applied in scenarios where additional management of discomfort is required to support the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Cardiac Strain

Ternolol is applied in addressing symptoms related to heightened physiological activity, and assists with maintaining functional stability in situations where patients experience rapid or irregular heart activity. This contributes to improved comfort during periods of symptomatic discomfort, and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview of Atenolol

Eligibility and Restrictions for Use

Ternolol (Atenolol) is explicitly contraindicated by regulatory authorities for several conditions. Absolute non-eligibility applies to patients with sinus bradycardia (slow heart rate), heart block greater than first degree, cardiogenic shock, and overt cardiac failure. Contraindications also include untreated pheochromocytoma, metabolic acidosis, severe peripheral arterial circulatory disturbances, and a history of hypersensitivity to atenolol.

Population Regulatory Eligibility Status
Pediatric Use Not Recommended. Safety and efficacy are not established in children.
Older Adults Use requires caution; dosage reduction may be necessary, especially with renal impairment.
Renal Impairment Use is restricted; mandatory dosage adjustment is required in patients with severe impairment of renal function due to renal excretion.

Use requires caution in patients with first-degree heart block or diabetes mellitus, where the drug may mask signs of hypoglycemia. For pregnancy, use is generally not recommended due to documented risks of fetal growth restriction. During lactation, use requires caution as the drug is excreted into breast milk, posing a risk of bradycardia and hypoglycemia to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ternolol (Atenolol) interaction patterns are defined by regulatory authorities based on two main mechanisms: pharmacodynamic synergy and pharmacokinetic absorption interference.

Documented Interaction Restrictions

Classification Interacting Agents Official Regulatory Statement
Contraindicated Verapamil and Diltiazem (IV route) Co-administration is prohibited due to the risk of severe hypotension and profound bradycardia from additive cardiac depressant effects.
Timing Separation Required Aluminum Hydroxide-containing antacids Ternolol must be administered at least 2 hours apart to prevent antacids from reducing the drug’s absorption, which lowers plasma concentration.
Procedural Withdrawal Rule Clonidine Ternolol must be withdrawn several days prior to the cessation of Clonidine to prevent the risk of rebound hypertension.

Other Clinically Relevant Interactions

Co-administration with other anti-arrhythmic drugs (e.g., Amiodarone, Digoxin) may result in an additive negative effect on heart rate and atrioventricular conduction. Similarly, combination with alcohol or other anti-hypertensive agents may lead to an enhanced hypotensive effect. Pharmacodynamic antagonism occurs with NSAIDs (e.g., Indomethacin), which may reduce the blood pressure-lowering effect of Ternolol. In patients with impaired renal function, elimination is slowed, potentially heightening the risk and severity of all interactions.

Mechanism of Action

Mechanism of Action: Ternolol

Ternolol functions as a selective competitive antagonist primarily targeting the mathbfbeta1-adrenergic receptors (beta1-ARs). These receptors are highly concentrated in the heart (myocardium) and the juxtaglomerular apparatus of the kidneys. The molecule competitively blocks the binding of endogenous catecholamines (e.g., norepinephrine), thereby inhibiting the associated Gs protein signaling cascade and the subsequent formation of intracellular cyclic AMP (cAMP).

In the myocardium, this inhibition results in decreased cardiac chronotropy (rate) and decreased cardiac inotropy (force of contraction). In the kidneys, antagonism of the beta1-ARs on juxtaglomerular cells suppresses the release of the enzyme renin, which initiates the Renin-Angiotensin-Aldosterone System (RAAS) cascade. Suppression of the RAAS diminishes the production of vasoconstrictive mediators, leading to reduced systemic vasoconstriction and decreased renal retention of sodium and water.

Dosage and Administration Information

Official Administration Guidelines

Administration of Ternolol (Atenolol) is dictated by specific routes and schedules outlined in clinical documentation. The medicine is primarily used via the oral route as a solid tablet, with an intravenous (IV) injection available for acute, in-hospital intervention, such as in the early phase of myocardial infarction.

For maintenance therapy, Ternolol is typically administered once daily. The usual oral starting dose for hypertension is 50 mg daily, which may be increased to 100 mg daily if the initial response is insufficient after one to two weeks. Doses exceeding 100 mg daily are generally not associated with increased benefit for hypertension. For angina pectoris, the daily dose may be up to 200 mg in certain patients, administered once daily or in divided doses.

Oral tablets should be swallowed whole with water and may be taken with or without food. Tablets with a score line may be divided to facilitate dosing. If a dose is missed, it should be taken as soon as remembered; however, if it is nearly time for the next scheduled dose, the missed dose is skipped to prevent taking a double dose.

Population-Specific Use

Because Ternolol is primarily eliminated by the kidneys, dose adjustment is mandated for patients with impaired renal function. For patients with a creatinine clearance between 15 and 35 mL/min/1.73 m^2, the oral dose should generally not exceed 50 mg daily. For clearance below 15 mL/min/1.73 m^2, the maximum daily dose is further reduced to 25 mg. For patients undergoing hemodialysis, 50 mg is typically administered after each session under hospital supervision. Use in the pediatric population is not recommended, as safety and efficacy have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ternolol

This overview describes the types of clinical research conducted on Ternolol (Atenolol), detailing the populations, the outcomes studied, and the known limitations, based on regulatory and scientific literature.


Evidence for Use in Hypertension (High Blood Pressure)

Research examining Ternolol in patients with high blood pressure has included both short-term Randomized Controlled Trials (RCTs) and long-term meta-analyses. These studies focused on adults, examining changes in Systolic and Diastolic Blood Pressure and long-term events like stroke and all-cause mortality. Findings describe patterns related to blood pressure readings in the observed populations. However, studies reported patterns of lower observed outcomes in reducing the long-term risk of stroke and all-cause mortality when comparing Ternolol to other agents. The certainty remains Moderate for its role in long-term event reduction relative to modern therapies due to the historical nature of much of the data.


Evidence for Use in Angina Pectoris (Chest Pain)

Ternolol was evaluated in numerous RCTs for managing chronic stable angina pectoris in adults. Researchers monitored the frequency of anginal episodes, the use of rescue medication, and exercise tolerance time. Findings indicate patterns related to changes in the number of anginal episodes and changes in exercise time. While the research base is consistent for studying these symptomatic and functional endpoints, long-term follow-up durations were often limited.


Evidence for Use Following a Heart Attack (Myocardial Infarction)

Ternolol was studied for use in patients stable after suffering a myocardial infarction (MI) in large RCTs focused on acute and secondary prevention use. Outcomes monitored included all-cause mortality and the risk of recurrent MI. Data show patterns related to the observed rate of these events in the studied populations. However, findings for long-term event rates in specific patient subgroups are currently a topic of ongoing research, particularly those who maintain normal heart function after the event.


What is Still Uncertain About Ternolol Research

One key area of uncertainty is the observed variation in findings when Ternolol was compared with certain newer drug classes for long-term cardiovascular events. This indicates that comparative evidence is lacking for some of the most critical endpoints. Furthermore, long-term effects are not fully established for all indications, and the evidence quality varies across studies. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions and group patterns under which they were conducted.

Key Studies & References

  1. Beta-blockers offer no clinical benefit for myocardial infarction survivors with preserved cardiac function (Contemporary meta-analysis)

Frequently Asked Questions (FAQ)

Common questions about Ternolol (FAQ)


Q: Can Ternolol be taken with food or does it need to be taken on an empty stomach?

A: According to the official administration guidelines, the medicine can be taken with or without food. Official data on drug absorption indicates that taking the medicine with food can be associated with a reduced amount of the drug absorbed.


Q: How quickly does Ternolol start working after you take it?

A: Regulatory information indicates that the first detectable effect on heart rate is typically apparent within approximately one hour after taking an oral dose. The maximum drug level in the body is generally reached between two and four hours after administration, which is when the most pronounced initial effects are typically observed.


Q: Does Ternolol have an immediate effect or does it build up over time?

A: The medicine has two distinct phases of action. While a significant initial effect on heart rate is observed within one hour of dosing, the full therapeutic effect, such as the full blood pressure-reducing effect, is generally observed over a period of one to two weeks of sustained use.


Q: Is Ternolol known to cause fatigue or tiredness?

A: Official safety documents describe tiredness and fatigue as adverse reactions. The classification of 'very common' indicates that these effects are documented to occur at a high rate.


Q: Is it common to feel dizzy when first starting Ternolol?

A: Regulatory information classifies dizziness as a common adverse reaction associated with the medicine.


Q: Is there a list of common side effects associated with Ternolol?

A: Official documents list adverse effects by frequency of occurrence. Common reactions include tiredness, fatigue, slow heart rate (bradycardia), cold extremities, gastrointestinal disturbances, and dizziness. This information is detailed further in the complete official safety profile.


Q: What are the possible changes to sleep patterns when taking Ternolol?

A: Official safety documents list sleep disturbances as an uncommon adverse reaction. More rare effects associated with the medicine may include nightmares.


Q: Are there any common supplements that interact with Ternolol?

A: Official guidance advises caution with many herbal remedies and supplements. This is because these products are generally not tested for their potential to interact with prescription medicines like Ternolol in the same way as other prescription drugs.


Q: Is Ternolol safe for use in older adults?

A: The use of the medicine in older adults is addressed in regulatory guidance. It is noted that initiating treatment at the low end of the dosing range may be necessary, often due to a greater frequency of reduced organ function, particularly in the kidneys.


Q: How long does the effect of one dose of Ternolol typically last?

A: Following a typical oral dose, the beta-blocking and blood pressure-reducing effects are reported to persist for at least 24 hours. The reported duration supports the medicine's usual administration once per day.


Q: Is Ternolol approved for use in children?

A: Official regulatory status is that the medicine is not recommended for use in children because its safety and efficacy have not been established in the pediatric population.


Q: Does Ternolol affect male sexual function?

A: Official safety documents list potential effects related to sexual function (such as decreased interest and difficulty with erections) as adverse reactions for which the incidence rate was not determined in clinical trials.


Q: What happens to the body when Ternolol starts working?

A: When the medicine begins to work, its primary physiological action is described as slowing the heart rate and decreasing the force of heart muscle contraction. This action helps to reduce the overall strain and energy demand on the heart.


Q: Is there a link between Ternolol and weight changes?

A: Some authoritative information suggests that weight gain can be an adverse reaction associated with this class of medicine. Studies have reported patterns related to weight gain that typically cease after the initial period of use.


Q: Is it possible to become dependent on Ternolol?

A: Official safety labeling requires a gradual reduction of the dose before stopping the medicine. The label states that abrupt discontinuation, particularly in individuals with Ischaemic Heart Disease, carries a documented potential for exacerbating heart-related conditions.


Q: Does Ternolol change cholesterol levels?

A: Authoritative information suggests that this medicine, as an older beta blocker, may be associated with slight changes in blood lipids. This can include a slight increase in triglycerides and a slight decrease in high-density lipoprotein (HDL) cholesterol.


Q: What is the risk of having an allergic reaction to Ternolol?

A: Hypersensitivity to the active ingredient is listed as an absolute contraindication for use. Signs of an allergic reaction are listed among the possible adverse experiences documented in the official safety profile.


Q: Do I need regular blood tests while I am taking Ternolol?

A: While the regulatory label does not mandate specific routine blood tests for all users, assessment of renal (kidney) function is required. This is important for dose adjustment, given that the kidney is the primary way the drug is eliminated from the body.


Q: What is the chemical or scientific name of Ternolol?

A: The active ingredient in the medicine is Atenolol. The substance is manufactured through chemical synthesis and has the formula C14H22N2O3.


Q: How long has Ternolol been available as a medicine?

A: The medicine containing the active ingredient Atenolol has been approved by regulatory bodies and available in some countries since the late 1970s and early 1980s.


Q: Is the effectiveness of Ternolol affected by my diet?

A: Studies on the drug’s absorption indicate that taking the medicine with food can reduce the amount of the drug absorbed. Administration guidelines permit taking the medicine with or without food.


Q: Is it possible for Ternolol to cause a cough?

A: Official safety information lists cough as one of the potential adverse reactions associated with the medicine.


Q: Does Ternolol cause dry mouth or dry eyes?

A: Official safety documents include dry mouth as a potential adverse reaction. The frequency of this experience was not determined in clinical trials.


Q: Does Ternolol have an impact on blood sugar levels?

A: Official labeling states that the medicine may affect blood glucose levels. The label also advises that the drug can mask certain physical signs of acute hypoglycemia (low blood sugar).


Q: What types of foods or drinks should be avoided while taking Ternolol?

A: The medicine can be taken with or without food. Some studies have suggested that administration directly with orange juice may reduce the medicine’s absorption. No specific food or drink contraindication is noted in the main regulatory documents.


Q: What is the typical timeframe to see the full effect of Ternolol?

A: The full therapeutic effect, particularly for blood pressure control, is generally observed within one to two weeks following the start of sustained treatment.


Q: How does Ternolol compare to other similar medicines in the same class?

A: Regulatory-cited research notes that comparative evidence is lacking for some critical endpoints when comparing this medicine to newer agents. Research findings have described patterns related to observed long-term outcomes, such as stroke reduction, when the medicine was examined in comparison with certain other drug agents.

How should Ternolol be stored and disposed of?

Official Storage and Disposal Requirements

Ternolol (Atenolol) must be stored under specific conditions defined by regulatory documents to maintain its stability and effectiveness. The tablets must be kept at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F).

Requirement Condition
Temperature Do not store above 25 C and do not freeze.
Environmental Protect from light, excessive heat, and moisture.
Container Keep in a tight, light-resistant container.
Child Safety Keep this and all medications out of the reach of children.
Disposal Dispose of unused or expired product according to local regulations.

Regulators instruct patients to consult a healthcare professional regarding the proper disposal methods for any unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ternolol found in:

A-Z Index: